Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 143

1.

Optimal use of targeted agents for advanced gastrointestinal stromal tumours.

Reichardt P.

Oncology. 2010;78(2):130-40. doi: 10.1159/000312655. Epub 2010 Apr 13. Review.

PMID:
20389135
2.

[The importance of mutational status in prognosis and therapy of GIST].

Comandone A, Boglione A.

Recenti Prog Med. 2015 Jan;106(1):17-22. doi: 10.1701/1740.18950. Italian.

PMID:
25621775
3.

Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.

Heinrich MC, Maki RG, Corless CL, Antonescu CR, Harlow A, Griffith D, Town A, McKinley A, Ou WB, Fletcher JA, Fletcher CD, Huang X, Cohen DP, Baum CM, Demetri GD.

J Clin Oncol. 2008 Nov 20;26(33):5352-9. doi: 10.1200/JCO.2007.15.7461. Epub 2008 Oct 27.

4.

Sunitinib as a second-line therapy for advanced GISTs after failure of imatinib: relationship between efficacy and tumor genotype in Korean patients.

Yoon DH, Ryu MH, Ryoo BY, Beck M, Choi DR, Cho Y, Lee JL, Chang HM, Kim TW, Kang YK.

Invest New Drugs. 2012 Apr;30(2):819-27. doi: 10.1007/s10637-010-9593-1. Epub 2010 Nov 23.

PMID:
21104107
5.

New paradigms in gastrointestinal stromal tumour management.

Blay JY.

Ann Oncol. 2009 May;20 Suppl 1:i18-24. doi: 10.1093/annonc/mdp075.

PMID:
19430004
6.

Efficacy and safety of sunitinib in Chinese patients with imatinib-resistant or -intolerant gastrointestinal stromal tumors.

Li J, Gao J, Hong J, Shen L.

Future Oncol. 2012 May;8(5):617-24. doi: 10.2217/fon.12.29.

PMID:
22646775
7.

Secondary mutations of c-KIT contribute to acquired resistance to imatinib and decrease efficacy of sunitinib in Chinese patients with gastrointestinal stromal tumors.

Gao J, Tian Y, Li J, Sun N, Yuan J, Shen L.

Med Oncol. 2013 Jun;30(2):522. doi: 10.1007/s12032-013-0522-y. Epub 2013 Mar 2.

PMID:
23456621
8.

Molecular basis for primary and secondary tyrosine kinase inhibitor resistance in gastrointestinal stromal tumor.

Gounder MM, Maki RG.

Cancer Chemother Pharmacol. 2011 Jan;67 Suppl 1:S25-43. doi: 10.1007/s00280-010-1526-3. Epub 2010 Nov 30. Review.

9.

[Gastrointestinal stromal tumors: molecular aspects and therapeutic implications].

Italiano A, Bui B.

Bull Cancer. 2008 Jan;95(1):107-16. doi: 10.1684/bdc.2008.0561. Review. French.

10.

[Secondary mutation of c-kit/PDGFRα genotypes after imatinib mesylate therapy and its relationship with efficacy of sunitinib].

Hong JL, Li J, Li J, Shen L.

Zhonghua Bing Li Xue Za Zhi. 2012 Jun;41(6):386-90. doi: 10.3760/cma.j.issn.0529-5807.2012.06.006. Chinese.

PMID:
22932406
11.

Imatinib escalation or sunitinib treatment after first-line imatinib in metastatic gastrointestinal stromal tumor patients.

Hsu CC, Wu CE, Chen JS, Tseng JH, Chiang KC, Liu YY, Tsai CY, Cheng CT, Chen TW, Jan YY, Yeh TS, Chen YY, Yeh CN.

Anticancer Res. 2014 Sep;34(9):5029-36.

PMID:
25202087
12.

[Gastrointestinal stromal tumour (GIST): current standards in multimodal management].

Reichardt P, Reichardt A.

Zentralbl Chir. 2011 Aug;136(4):359-63. doi: 10.1055/s-0031-1271596. Epub 2011 Aug 23. Review. German.

PMID:
21863513
13.

Advanced gastrointestinal stromal tumor in Europe: a review of updated treatment recommendations.

Blay JY, Reichardt P.

Expert Rev Anticancer Ther. 2009 Jun;9(6):831-8. doi: 10.1586/era.09.34. Review.

PMID:
19496720
14.

The role of KIT in the management of patients with gastrointestinal stromal tumors.

Hornick JL, Fletcher CD.

Hum Pathol. 2007 May;38(5):679-87. Review.

PMID:
17437861
15.

The outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure - one institution study.

Rutkowski P, Bylina E, Klimczak A, Switaj T, Falkowski S, Kroc J, Lugowska I, Brzeskwiniewicz M, Melerowicz W, Osuch C, Mierzejewska E, Wasielewski K, Woźniak A, Grzesiakowska U, Nowecki ZI, Siedlecki JA, Limon J.

BMC Cancer. 2012 Mar 22;12:107. doi: 10.1186/1471-2407-12-107.

16.

Imatinib for the treatment of patients with unresectable and/or metastatic gastrointestinal stromal tumours: systematic review and economic evaluation.

Wilson J, Connock M, Song F, Yao G, Fry-Smith A, Raftery J, Peake D.

Health Technol Assess. 2005 Jul;9(25):1-142. Review.

17.

Heterogeneity of kinase inhibitor resistance mechanisms in GIST.

Liegl B, Kepten I, Le C, Zhu M, Demetri GD, Heinrich MC, Fletcher CD, Corless CL, Fletcher JA.

J Pathol. 2008 Sep;216(1):64-74. doi: 10.1002/path.2382.

18.

Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group.

Heinrich MC, Owzar K, Corless CL, Hollis D, Borden EC, Fletcher CD, Ryan CW, von Mehren M, Blanke CD, Rankin C, Benjamin RS, Bramwell VH, Demetri GD, Bertagnolli MM, Fletcher JA.

J Clin Oncol. 2008 Nov 20;26(33):5360-7. doi: 10.1200/JCO.2008.17.4284. Epub 2008 Oct 27.

19.

Gastrointestinal stromal tumors.

Antonescu C.

Curr Top Microbiol Immunol. 2012;355:41-57. doi: 10.1007/82_2011_161. Review.

PMID:
22015552
20.

Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib.

Janeway KA, Albritton KH, Van Den Abbeele AD, D'Amato GZ, Pedrazzoli P, Siena S, Picus J, Butrynski JE, Schlemmer M, Heinrich MC, Demetri GD.

Pediatr Blood Cancer. 2009 Jul;52(7):767-71. doi: 10.1002/pbc.21909.

PMID:
19326424

Supplemental Content

Support Center